Global Ltd Gull Sells 40,000 Shares of USANA Health Sciences, Inc. (USNA) Stock

Share on StockTwits

USANA Health Sciences, Inc. (NYSE:USNA) major shareholder Global Ltd Gull sold 40,000 shares of the business’s stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $126.74, for a total transaction of $5,069,600.00. Following the transaction, the insider now owns 10,048,831 shares in the company, valued at approximately $1,273,588,840.94. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Global Ltd Gull also recently made the following trade(s):

  • On Tuesday, August 21st, Global Ltd Gull sold 60,000 shares of USANA Health Sciences stock. The shares were sold at an average price of $131.35, for a total transaction of $7,881,000.00.
  • On Thursday, August 9th, Global Ltd Gull sold 90,000 shares of USANA Health Sciences stock. The shares were sold at an average price of $131.03, for a total transaction of $11,792,700.00.
  • On Monday, August 6th, Global Ltd Gull sold 100,000 shares of USANA Health Sciences stock. The shares were sold at an average price of $131.00, for a total transaction of $13,100,000.00.
  • On Tuesday, July 31st, Global Ltd Gull sold 100,000 shares of USANA Health Sciences stock. The shares were sold at an average price of $131.50, for a total transaction of $13,150,000.00.
  • On Thursday, August 2nd, Global Ltd Gull sold 140,000 shares of USANA Health Sciences stock. The shares were sold at an average price of $130.69, for a total transaction of $18,296,600.00.
  • On Monday, July 2nd, Global Ltd Gull sold 30,796 shares of USANA Health Sciences stock. The shares were sold at an average price of $115.18, for a total transaction of $3,547,083.28.
  • On Tuesday, December 4th, Global Ltd Gull sold 6,681 shares of USANA Health Sciences stock. The shares were sold at an average price of $70.47, for a total transaction of $470,810.07.
  • On Saturday, December 1st, Global Ltd Gull sold 12,436 shares of USANA Health Sciences stock. The shares were sold at an average price of $70.45, for a total transaction of $876,116.20.
  • On Tuesday, December 11th, Global Ltd Gull bought 10,396 shares of USANA Health Sciences stock. The shares were bought at an average price of $70.70 per share, for a total transaction of $734,997.20.
  • On Saturday, December 8th, Global Ltd Gull bought 824 shares of USANA Health Sciences stock. The shares were bought at an average price of $70.70 per share, for a total transaction of $58,256.80.

USANA Health Sciences stock opened at $123.50 on Friday. USANA Health Sciences, Inc. has a 12-month low of $55.50 and a 12-month high of $137.95. The firm has a market cap of $3.05 billion, a P/E ratio of 30.74 and a beta of 0.64.

USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, July 24th. The company reported $1.36 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.11 by $0.25. USANA Health Sciences had a net margin of 7.16% and a return on equity of 29.50%. The company had revenue of $301.50 million for the quarter, compared to the consensus estimate of $278.41 million. During the same quarter in the previous year, the company earned $0.98 EPS. USANA Health Sciences’s quarterly revenue was up 17.3% compared to the same quarter last year. research analysts expect that USANA Health Sciences, Inc. will post 4.9 earnings per share for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN raised its holdings in USANA Health Sciences by 5.8% during the first quarter. Wells Fargo & Company MN now owns 110,701 shares of the company’s stock worth $9,509,000 after buying an additional 6,033 shares during the last quarter. SG Americas Securities LLC acquired a new position in USANA Health Sciences during the first quarter worth $137,000. DekaBank Deutsche Girozentrale raised its holdings in USANA Health Sciences by 239.5% during the first quarter. DekaBank Deutsche Girozentrale now owns 27,072 shares of the company’s stock worth $2,345,000 after buying an additional 19,099 shares during the last quarter. Mackay Shields LLC acquired a new position in USANA Health Sciences during the first quarter worth $3,780,000. Finally, State Board of Administration of Florida Retirement System acquired a new position in USANA Health Sciences during the first quarter worth $236,000. Institutional investors own 56.38% of the company’s stock.

Separately, Pivotal Research reiterated a “hold” rating and set a $135.00 target price on shares of USANA Health Sciences in a research report on Wednesday, July 25th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $135.00.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Recommended Story: How to Invest in an Index Fund

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply